Soligenix Announces Publication of its Phase 2 Clinical Trial Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

PRINCETON N.J. Oct. 18 2016 PRNewswire Soligenix Inc. OTCQB SNGXD Soligenix or the Company a latestage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need announced today...